Semi-solid Lipid Formulation for Sustained Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional controlled drug delivery systems, particularly semi-solid formulations, face issues with initial drug burst, inconsistent release kinetics, and manufacturing complexity, leading to unreliable therapeutic effects in animal and human trials.
Innovation Solution
A semi-solid gel formulation comprising glycerides with specific alkyl chains and active ingredients like meloxicam, loteprednol, or granisetron, combined with modifying excipients to achieve controlled release kinetics and reduced viscosity, allowing for prolonged drug release and easy injection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If semi-solid polymer formulations are used for controlled drug delivery, then prolonged drug release is achieved, but the formulations become very sticky and cannot be easily injected
Solution Approach 1:
The patent changes the physical and chemical parameters of the semi-solid formulation by adjusting polymer concentration, molecular weight, and composition to reduce viscosity and stickiness while maintaining controlled release properties, enabling easy injection
Solution Approach 2:
The patent uses composite material systems combining semi-solid polymers with lipids or other excipients to create formulations that balance viscosity, stability, and injectability while achieving prolonged drug release
2Duration of action of moving object
If conventional controlled drug delivery systems are used, then drug release is extended, but initial drug burst and inconsistent release kinetics occur
Solution Approach 1:
The patent applies local quality by creating heterogeneous polymer matrices with different degradation rates or drug loading densities in different regions, allowing control over initial burst while maintaining consistent overall release kinetics
Solution Approach 2:
The patent uses preliminary action by pre-treating the polymer matrix or pre-complexing the drug with the polymer before formulation, which prevents initial drug burst and ensures consistent release kinetics from the start of administration
3Duration of action of moving object
If microencapsulation systems are used for sustained release, then drug delivery is controlled, but manufacturing processes become complicated, cumbersome and expensive
Solution Approach 1:
The patent extracts the complex microencapsulation process and replaces it with simpler semi-solid formulation techniques, eliminating the need for sophisticated encapsulation equipment while maintaining sustained release capability
Solution Approach 2:
The patent employs simpler, more disposable-friendly formulation approaches that can be manufactured using basic equipment, reducing manufacturing complexity and cost compared to durable microencapsulation systems
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation provides sustained drug release for several days to months with reduced initial burst, improved therapeutic efficacy, and ease of administration, while being less painful and less voluminous, thus enhancing patient compliance and reducing side effects.
Implementation Method 1
A drug delivery vehicle most often consists of a polymeric matrix from which drug is released by diffusion from the matrix
Implementation Method 2
A drug delivery vehicle most often consists of a polymeric matrix from which drug is released by diffusion from the matrix and/or by degradation of the matrix
Implementation Method 3
a second excipient consisting of one or more glycerides having a structure selected from formulas I, II, III, IV, or V, in which the second excipient is fully miscible with the semi-solid gel, in which the second excipient modifies the viscosity of the pharmaceutical composition to 20 to 2000 cPs at 30° C.
Data Source
AI summary
What is described is a semi-solid controlled release composition comprising a semi-solid lipid pharmaceutical active agent in a solution or a homogenous suspension, methods of using the composition for treating a disease, and methods of manufacturing the composition.